{
    "root": "30c5f882-6c42-756d-e063-6394a90a8a10",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atomoxetine Hydrochloride",
    "value": "20250320",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ATOMOXETINE HYDROCHLORIDE",
            "code": "57WVB6I2W0"
        }
    ],
    "indications": "atomoxetine selective norepinephrine reuptake inhibitor indicated treatment attention-deficit/hyperactivity disorder ( adhd ) . ( 1.1 )",
    "contraindications": "initial , target maximum daily dose ( 2.1 ) ( acute maintenance/extended treatment ) body weight initial daily dose target total daily dose maximum total daily dose children adolescents 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg children adolescents 70 kg adults 40 mg 80 mg 100 mg dosing adjustment — hepatic impairment , strong cyp2d6 inhibitor , patients known cyp2d6 poor metabolizers ( pms ) . ( 2.5 , 12.3 )",
    "warningsAndPrecautions": "atomoxetine capsules , usp 10 mg available oral hard gelatin capsules white opaque body white opaque cap , imprinted “ apo am10 ” black ink . supplied follows : ndc : 70518-4313-00 ndc : 70518-4313-01 packaging : 30 1 box packaging : 1 1 pouch store atomoxetine capsules , usp 20°c 25°c ( 68°f 77°f ) excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "hypersensitivity atomoxetine constituents product . ( 4.1 ) atomoxetine within 2 weeks discontinuing maoi drugs affect brain monoamine concentrations . ( 4.2 , 7.1 ) narrow angle glaucoma . ( 4.3 ) pheochromocytoma history pheochromocytoma . ( 4.4 ) severe cardiovascular disorders might deteriorate clinically important increases hr bp . ( 4.5 )",
    "indications_original": "Atomoxetine is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). ( 1.1 )",
    "contraindications_original": "Initial, Target and Maximum Daily Dose (2.1) (Acute and Maintenance/Extended Treatment) Body Weight Initial Daily Dose Target Total Daily Dose Maximum Total Daily Dose Children and adolescents up to 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg Children and adolescents over 70 kg and adults 40 mg 80 mg 100 mg Dosing adjustment — Hepatic Impairment, Strong CYP2D6 Inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs). ( 2.5 , 12.3)",
    "warningsAndPrecautions_original": "Atomoxetine capsules, USP 10 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap, imprinted “APO AM10” in black ink. They are supplied as follows:\n                  \n                  NDC: 70518-4313-00\n                  NDC: 70518-4313-01\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Store atomoxetine capsules, USP at 20°C to 25°C (68°F to 77°F) excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Hypersensitivity to atomoxetine or other constituents of product. ( 4.1 ) Atomoxetine use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations. ( 4.2 , 7.1 ) Narrow Angle Glaucoma. ( 4.3 ) Pheochromocytoma or history of pheochromocytoma. ( 4.4 ) Severe Cardiovascular Disorders that might deteriorate with clinically important increases in HR and BP. ( 4.5 )"
}